Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations
About this study
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
- Condition
- Non Small Cell Lung Carcinoma NSCLC
- Tested
- Progression free survival, Overall survival
- Sponsor
- University of Malaya
Who can join
- Age
- 65 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 65 years
- Study condition: Non Small Cell Lung Carcinoma NSCLC
- Age ≥65 years
- Histologically confirmed stage IV NSCLC
- Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
- Treated with at least ONE cycle of first-line chemotherapy
Exclusion 2
- Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
- Incomplete survival data
Where
4 sites, 4 recruiting
Queen Mary Hospital, The University of Hong Kong
Hong Kong, Hong Kong
Hospital Wanita dan Kanak-Kanak Sabah
Kota Kinabalu, Sabah, Malaysia
Universiti Malaya Medical Centre
Kuala Lumpur, Malaysia
Hospital Tengku Ampuan Afzan
Kuantan, Pahang, Malaysia
Contact
-
Mau Ern Poh, MBBS
+60379494422 ernestpoh@um.edu.my
-
Danouska Bala Krishnan
+603-79492351 danouska@ummc.edu.my
Potential match only. Final eligibility is determined by the study team.